The purpose of this study is to assess the incidence of cardiovascular events in patients
with esophageal/stomach or colorectal cancer treated by trifluridine/tipiracil +/-
oxaliplatin after an episode of cardiac angina-related thoracic pain due to fluoropyrimidines
in the adjuvant or metastatic setting .
After being informed about the study and potential risks, all patients giving written
informed consent will undergo a 14-day screening period to determine eligibility for study
entry. Patient who meet the eligibility requirement will be included in the study and will be
treated by trifluridine/tipiracil +/- oxaliplatin.
Colorectal Adenocarcinoma, Oesogastric
Clinical Study Identifier
GERCOR - Multidisciplinary Oncology Cooperative Group
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.